Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure
Iacopo Gesmundo,Michele Miragoli,Pierluigi Carullo,Letizia Trovato,Veronica Larcher,Elisa Di Pasquale,Mara Brancaccio,Marta Mazzola,Tania Villanova,Matteo Sorge,Marina Taliano,Maria Pia Gallo,Giuseppe Alloatti,Claudia Penna,Joshua M Hare,Ezio Ghigo,Andrew V Schally,Gianluigi Condorelli,Riccarda Granata,Joshua M. Hare,Andrew V. Schally
DOI: https://doi.org/10.1073/pnas.1712612114
IF: 11.1
2017-10-25
Proceedings of the National Academy of Sciences
Abstract:Significance Pathological cardiac hypertrophy, characterized by heart growth in response to pressure or volume overload, such as in the setting of hypertension, is the main risk factor for heart failure (HF). The identification of therapeutic strategies to prevent or reverse cardiac hypertrophy is therefore a priority for curing HF. It is known that growth hormone-releasing hormone (GHRH) displays cardioprotective functions; however, its therapeutic potential in hypertrophy and HF is unknown. Here we show that GHRH reduces cardiomyocyte hypertrophy in vitro through inhibition of hypertrophic pathways. In vivo, the GHRH analog MR-409 attenuates cardiac hypertrophy in mice subjected to transverse aortic constriction and improves cardiac function. These findings suggest therapeutic use of GHRH analogs for treatment of pathological cardiac hypertrophy and HF.
multidisciplinary sciences